Bristol Myers Squibb Co. (NYSE: BMY) agreed to buy schizophrenia drug developer Karuna Therapeutics Inc. for $14 billion, gaining a promising treatment that’s approaching the market.
To read the entire story, you must be logged in.
Please log in now or register with us.
